• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Video Highlights from ASCO and EHA 2019

by MM360 Staff | Jun 25, 2020 | Featured News, Myeloma News, Videos

We just added a series of videos with two of the world leading experts in the treatment of myeloma. Dr. Xavier Leleu from the Centre Hospitalier Universitaire de Lille and Dr. Sagar Lonial from Emory University School of Medicine discuss the highlights of new myeloma...

Dr. Karim Iskander: EHA 2018 Abstract S849

by MM360 Staff | Jul 13, 2018 | EHA 2018, Featured News, Videos

Once-Weekly Vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W. Authors: Maria-Victoria Mateos , Philippe Moreau , James R. Berenson , Katja Weisel ,...

Dr. Paul Richardson: EHA 2018 Abstract S847

by MM360 Staff | Jul 12, 2018 | EHA 2018, Featured News, Videos

OPTIMISMM: Phase 3 Trial of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with Relapsed/Refractory Multiple Myeloma Author(s): Paul Richardson , Albert Oriol Rocafiguera , Meral Beksac ,...

Dr. Friend on the Importance of Work-up for Patients With Multiple Myeloma

by OncLive | Jan 19, 2018 | Myeloma News, Videos

Reed Friend, MD discusses the importance of appropriate work-ups for patients with multiple myeloma. Reed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of...

Mechanism of Action (MOA) and Its Impact on Multiple Myeloma Treatment

by Expert Panel Members | Dec 10, 2017 | ASH 2017, Videos

Dr. Rafael Fonseca from the Mayo Clinic in Phoenix Arizona discusses mechanism of action and how that is being looked at in the application of multiple myeloma and treatment. Important research impacting our understanding of proteosome inhibitors, and IMiD is...

Latest Data in Newly Diagnosed Multiple Myeloma

by Expert Panel Members | Dec 4, 2017 | ASH 2017, Videos

World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 in Newly Diagnosed Multiple Myeloma including: Abstract LBA-4:Phase 3 Randomized Study of Daratumumab...

Recent Content

  • Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT